390亿美元！西门子分拆医疗业务

Core Viewpoint - Siemens is implementing a significant equity restructuring plan by transferring shares of Siemens Healthineers worth €33.5 billion (approximately $39.07 billion) to its shareholders, marking a step towards the independent operation of Siemens Healthineers [1] Group 1: Equity Restructuring - Siemens currently holds 67% of Siemens Healthineers and plans to transfer 30% of its shares to shareholders, reducing its stake to 37% or below [1] - The CEO of Siemens, Roland Busch, indicated that the company aims to lower its stake to below 20% in the medium term, potentially initiating further reductions before the approval of the current plan [1] Group 2: Strategic Focus - The restructuring is intended to allow Siemens to concentrate on its core businesses, specifically factory and building automation, as well as rail transportation manufacturing [1] - Busch emphasized that both companies will operate in a more focused and flexible manner post-split, with Siemens prioritizing software and digital business integration [2] Group 3: Market Response and Implications - The announcement has resolved investor uncertainties regarding Siemens' investment strategy in the healthcare sector, receiving positive feedback from Siemens Healthineers' CEO, Bernd Montag [2] - Analysts believe that the elimination of equity uncertainty could significantly boost Siemens Healthineers' stock performance [2] Group 4: Tax and Strategic Benefits - The current share transfer plan is seen as more tax-efficient compared to a cash dividend distribution, which could incur substantial tax liabilities [3] - This asset adjustment is viewed as a hallmark strategic move by CEO Busch, aligning with the demands of major shareholders for a more focused industrial business [3] Group 5: Leadership Changes - Siemens announced a leadership change, with CFO Ralf Thomas set to step down in fiscal year 2026, to be succeeded by Veronika Bienert, the CEO of Siemens Financial Services [3] - Thomas will continue to participate in the healthcare sector as a member of the supervisory board of Siemens Healthineers [3] Group 6: Future Considerations - The specific timeline for the equity restructuring has not been disclosed, and the approval process will be a focal point for the industry [3] - The restructuring is expected to reshape the equity relationship between Siemens and Siemens Healthineers and may have far-reaching effects on the global medical device industry [3]